Hyperhydration is not necessary for high-dose melphalan in stem cell transplantation
Sign Up to like & getrecommendations! Published in 2019 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-019-0586-1
Abstract: To the Editor, High-dose melphalan (120–200 mg/m) is widely used in preparative regimens for autologous and allogeneic haematopoietic stem cell transplantation (HSCT). This drug is often given with “hyperhydration” that usually means 4–6 litres (L)… read more here.
Keywords: autologous hsct; hyperhydration; melphalan; transplantation ... See more keywords
Efficacy and safety of autologous hematopoietic stem cell therapy for refractory Crohn's disease
Sign Up to like & getrecommendations! Published in 2017 at "Medicine"
DOI: 10.1097/md.0000000000007381
Abstract: Background: Autologous hematopoietic stem cell transplantation (HSCT) has been proposed for patients with refractory Crohn's disease (CD), but it is associated with mortality and adverse events; the balance between risks and benefits becomes significantly important… read more here.
Keywords: therapy; refractory; efficacy safety; autologous hsct ... See more keywords
Latent tuberculosis in adult hematopoietic stem cell transplantation recipients: Clinical experience from a previously endemic population
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000031786
Abstract: Hematopoietic stem cell transplantation (HSCT) recipients may be at an elevated risk of developing active tuberculosis infection due to suppression in the cellular immune system. Herein, we aimed to evaluate the prevalence of latent tuberculosis… read more here.
Keywords: allogeneic hsct; tuberculosis; patients allogeneic; autologous hsct ... See more keywords
Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis
Sign Up to like & getrecommendations! Published in 2022 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/ard-2021-221925
Abstract: Objectives Myeloablative autologous haematopoietic stem cell transplant (HSCT) was recently demonstrated to provide significant benefit over cyclophosphamide (CYC) in the treatment of diffuse cutaneous systemic sclerosis (dcSSc) in the Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial.… read more here.
Keywords: cell; haematopoietic stem; myeloablative autologous; autologous hsct ... See more keywords